The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies

Jia Ling Li, Guo Liang Shen, Maria Ana Ghetie, Richard D. May, Mark Till, Victor Ghetie, Jonathan W. Uhr, George Janossy, Philip E. Thorpe, Peter Amlot, Ellen S. Vitetta

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.

Original languageEnglish (US)
Pages (from-to)85-99
Number of pages15
JournalCellular Immunology
Volume118
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Organ Specificity
Epitopes
Anti-Idiotypic Antibodies
B-Lymphocytes
Monoclonal Antibodies
Antibodies
Sialic Acid Binding Ig-like Lectin 2
Immunotoxins
Cell Line
varespladib methyl
Fluorescent Antibody Technique
Neoplasms

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. / Li, Jia Ling; Shen, Guo Liang; Ghetie, Maria Ana; May, Richard D.; Till, Mark; Ghetie, Victor; Uhr, Jonathan W.; Janossy, George; Thorpe, Philip E.; Amlot, Peter; Vitetta, Ellen S.

In: Cellular Immunology, Vol. 118, No. 1, 1989, p. 85-99.

Research output: Contribution to journalArticle

Li, JL, Shen, GL, Ghetie, MA, May, RD, Till, M, Ghetie, V, Uhr, JW, Janossy, G, Thorpe, PE, Amlot, P & Vitetta, ES 1989, 'The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies', Cellular Immunology, vol. 118, no. 1, pp. 85-99. https://doi.org/10.1016/0008-8749(89)90359-6
Li, Jia Ling ; Shen, Guo Liang ; Ghetie, Maria Ana ; May, Richard D. ; Till, Mark ; Ghetie, Victor ; Uhr, Jonathan W. ; Janossy, George ; Thorpe, Philip E. ; Amlot, Peter ; Vitetta, Ellen S. / The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. In: Cellular Immunology. 1989 ; Vol. 118, No. 1. pp. 85-99.
@article{23f7cc3ed9a449128906f012ae4acaa1,
title = "The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies",
abstract = "The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.",
author = "Li, {Jia Ling} and Shen, {Guo Liang} and Ghetie, {Maria Ana} and May, {Richard D.} and Mark Till and Victor Ghetie and Uhr, {Jonathan W.} and George Janossy and Thorpe, {Philip E.} and Peter Amlot and Vitetta, {Ellen S.}",
year = "1989",
doi = "10.1016/0008-8749(89)90359-6",
language = "English (US)",
volume = "118",
pages = "85--99",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies

AU - Li, Jia Ling

AU - Shen, Guo Liang

AU - Ghetie, Maria Ana

AU - May, Richard D.

AU - Till, Mark

AU - Ghetie, Victor

AU - Uhr, Jonathan W.

AU - Janossy, George

AU - Thorpe, Philip E.

AU - Amlot, Peter

AU - Vitetta, Ellen S.

PY - 1989

Y1 - 1989

N2 - The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.

AB - The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=0024536868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024536868&partnerID=8YFLogxK

U2 - 10.1016/0008-8749(89)90359-6

DO - 10.1016/0008-8749(89)90359-6

M3 - Article

VL - 118

SP - 85

EP - 99

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 1

ER -